Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Bill Haynes

Head of Novo Nordisk Research Centre Oxford (NNRCO), Novo Nordisk A/S

Bill Haynes leads the new Novo Nordisk Research Centre Oxford, which has a goal of discovering novel targets and game-changing therapies across cardiometabolic diseases. Novo Nordisk has committed more than £115m to this transformational research centre with a focus on human
translational and computational biology.

Bill is a physician-scientist with more than 25 years of experience in academic-industry translational research in cardiometabolic disease, supported by Wellcome, National Institutes of Health (NIH), Juvenile Diabetes Research Foundation, and Swedish Foundation for Strategic Research. Bill trained in medicine and translational research in the UK and was a Professor of Endocrinology and Cardiovascular diseases at the University of Iowa. In 2013, Bill transitioned to the pharma industry, working in discovery research and translational medicine at Novartis and AstraZeneca, and driving novel targets in diabetes, non alcoholic steatohepatitis (NASH), cardiovascular (CV) disease and obesity towards clinical development. He has led multiple high-profile collaborations with academic institutions including the MRC, Harvard, INSERM and the Karolinska Institute.

Bill is a fellow of the American Heart Association and The Obesity Society and an elected member of the American Society of Clinical Investigation. Bill has been recently appointed a Visiting Professor in RDM, University of Oxford.